Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Drug

Novo Nordisk’s Anti-Obesity Drug Wegovy Eyed for China Launch in 2024

Fineline Cube Mar 8, 2024

Novo Nordisk (NYSE: NVO), a leading diabetes company based in Denmark, has reportedly informed investors...

Company Drug

China Grand Pharmaceutical Receives FDA Approval for Post-Surgical Ophthalmic Drug GPN00833

Fineline Cube Mar 8, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced that it has...

Company Drug

Shanghai Fosun Pharma Gets NMPA Green Light for XS-02 Solid Tumor Clinical Study

Fineline Cube Mar 8, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company Deals

Everest Medicines to Establish Integrated Kidney Disease Diagnosis and Treatment Ecosystem

Fineline Cube Mar 7, 2024

Everest Medicines (HKG: 1952), a Chinese pharmaceutical company, is set to collaborate with partners to...

Company Drug

Boehringer Ingelheim’s Spevigo Receives NMPA Approval for GPP Treatment in China

Fineline Cube Mar 7, 2024

German pharmaceutical giant Boehringer Ingelheim (BI) has announced that it has received marketing approval from...

Company Deals

Zylox-Tonbridge Medical Technology Secures Licensing Deal with Avinger to Boost Device Portfolio

Fineline Cube Mar 7, 2024

Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices,...

Company Deals

BeiGene Subsidiary Pi Health Cayman to be Merged in Deal Valued at $41.8 Million

Fineline Cube Mar 7, 2024

BeiGene (NASDAQ: BGNE) has announced that Delaware-based Pi Health Inc. is set to absorb and...

Company Drug

Luye Pharma Launches Small-Cell Lung Cancer Treatment Zepzelca in Hong Kong and Macau

Fineline Cube Mar 7, 2024

Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced the official market launch...

Company Deals

Proviva Therapeutics Secures $18 Million in Series A Financing to Advance PTX-912

Fineline Cube Mar 7, 2024

Proviva Therapeutics, a Shanghai-based clinical-stage biotechnology company, has reportedly secured USD 18 million in a...

Legal / IP Policy / Regulatory

US Senate Committee Backs Bill to Restrict Chinese Biotechnology Firms’ Access to American Genetic Data

Fineline Cube Mar 7, 2024

The U.S. Senate’s homeland security committee has voted 11-1 in favor of the Prohibiting Foreign...

Company Drug

CARsgen Launches BCMA-Targeted CAR-T Therapy in China with High Price Point

Fineline Cube Mar 7, 2024

China-based CAR-T cell therapy specialist CARsgen Therapeutics Holdings Ltd. (HKG: 2171) has launched its BCMA-targeted...

Company Drug

Xian Janssen’s Tremfya Heads for Priority Review in China for Crohn’s Disease Treatment

Fineline Cube Mar 7, 2024

The Center for Drug Evaluation (CDE) has indicated that Xian Janssen Pharmaceutical’s Tremfya (guselkumab), an...

Company Drug

EMA Reviews J&J’s Darzalex Subcutaneous Formulation for Newly Diagnosed Multiple Myeloma

Fineline Cube Mar 7, 2024

The European Medicines Agency (EMA) has this week received an indication extension filing from Johnson...

Company Drug

Gilead and MSD Report Positive Interim Data for Once-Weekly HIV Treatment in Phase II Trial

Fineline Cube Mar 7, 2024

Gilead Sciences Inc. (NASDAQ: GILD) and Merck & Co., Inc., known as MSD (NYSE: MRK),...

Company Deals

Gilead and Merus Form Strategic Oncology Alliance to Develop Trispecific T-Cell Engagers

Fineline Cube Mar 7, 2024

Gilead Sciences Inc., (NASDAQ: GILD), has entered into a strategic partnership with Netherlands-based Merus N.V....

Company Drug

Henlius Biotech’s HER2 Targeting Biosimilar Secures Thai and Philippine Approvals

Fineline Cube Mar 7, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696) a leading China-based biotech firm, has announced that its...

Company Deals

Lee’s Pharmaceutical Secures Malaysian Distribution for Generic Glaucoma Treatment

Fineline Cube Mar 7, 2024

Lee’s Pharmaceutical Holdings Ltd., (HKG: 0950), a China-based pharmaceutical company, has announced through its subsidiary...

Company

Sino Medical Sciences Gains Pakistani Nod for SC HONKYTONK and NC ROCKSTAR Catheters

Fineline Cube Mar 6, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108) a Chinese medical device company, has announced that...

Company Drug

Duality Biologics’ DB-1303 on Track for Breakthrough Designation for HER2+ Endometrial Cancer

Fineline Cube Mar 6, 2024

The Center for Drug Evaluation (CDE) website has indicated that DB-1303, a HER2 targeted antibody...

Company Deals

Apeloa Pharmaceutical and ZhenGe Biotech Join Forces to Create Comprehensive ADC Platform

Fineline Cube Mar 6, 2024

China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has entered into a strategic partnership with domestic...

Posts pagination

1 … 446 447 448 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.